Skip to content

Luteal Phase Supplementation With Recombinant LH After GnRh Agonist Oocytes Triggering in Women at Risk of OHSS

Luteal Phase Supplementation With Recombinant LH After GnRh Agonist Oocytes Triggering in Women at Risk of OHSS

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02200952
Enrollment
16
Registered
2014-07-25
Start date
2013-06-30
Completion date
2014-06-30
Last updated
2020-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Hyperstimulation Syndrome

Keywords

OHSS, Oocytes triggering, GnRh agonist triggering, Luteal phase supplementation, recombinant LH

Brief summary

The purpose of this study is to prove that luteal phase supplementation with recombinant LH can solve the luteal phase deficiency after Gnrh agonist oocytes triggering in women at risk of OHSS

Detailed description

The investigators enrolled patients, undergoing controlled ovarian stimulation for an IVF/ICSI cycles, who on the day of oocytes triggering were at risk of OHSS. These patients had an estradiol \> 4000 pg/ml and more than 24 follicles with a diameter greater than 12 mm. The investigators used 0,2 mg of triptorelin for the oocytes triggering and supplemented the luteal phase with recombinant LH at a dose of 75 UI twice/day for 10 days and vaginal gel progesterone and oral oestradiol for 14 days The investigators measured bhCG at 14 days from the pick up. In case of positive bhCG we have defined the IVF/ICSI outcome: Pregnancy Rate and Implantation Rate.

Interventions

recombinant LH twice/day for 10 days from pick up

Sponsors

San Carlo Public Hospital, Potenza, Italy
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 43 Years
Healthy volunteers
No

Inclusion criteria

* patients with an oestradiol \> 4000 pg/ml on the oocytes triggering day * patient with more than 24 follicles of diameter greater than 12 mm on the oocytes triggering day

Exclusion criteria

* patients with no risk of OHSS on the oocytes triggering day * patients with an oestradiol \< 4000 pg/ml on the oocytes triggering day * patient with less than 24 follicles of diameter greater than 12 mm on the oocytes triggering day

Design outcomes

Primary

MeasureTime frameDescription
Pregnancy Rate and Implantation RateFrom 14 days after the pick up to six weeks of gestationWe measured bhCG after 14 days from the pick up. In presence of a positive value of bhCG we evaluated IVF/ICSI outcome through the pregnancy rate and implantation rate.

Secondary

MeasureTime frameDescription
Ealy and Late Ovarian Hyperstimulation SyndromeFrom 9 days after pick up to 12 weeks of gestationWe evaluated early and late ovarian hyperstimulation syndrome according the practice committee of ASRM 2008 and Current Clinical Guideline for OHSS of 2010

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026